PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19
Palo Alto (17 mi)Age: 18 - 65
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Pardes Biosciences, Inc.
Prior Safety Data
Trial Summary
What is the purpose of this trial?This trial tests a new antiviral medicine called PBI-0451 (Pomotrelvir) on adults with COVID-19 who have symptoms but are not hospitalized. The medicine aims to stop the virus from multiplying, helping patients recover faster.
Eligibility Criteria
Treatment Details
2Treatment groups
Experimental Treatment
Placebo Group
Group I: PBI-0451 (Pomotrelvir)Experimental Treatment1 Intervention
PBI-0451(Pomotrelvir): 2 x 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
Group II: PlaceboPlacebo Group1 Intervention
PBI-0451(Pomotrelvir): 2 x placebo to match PBI-0451(Pomotrelvir) tablets administered orally twice daily (BID) with food for 5 days (10 total doses)
Find a clinic near you
Research locations nearbySelect from list below to view details:
CTMD Research, Inc. - Palm Springs - Hunt - PPDSPalm Springs, FL
Allianz Research Institute - ColoradoWestminster, CA
Florida International Medical ResearchMiami, FL
Franco A Felizarta MDBakersfield, CA
More Trial Locations
Loading ...
Who is running the clinical trial?
Pardes Biosciences, Inc.Lead Sponsor